Progress of CD47 immune checkpoint blockade agents in anticancer therapy: a hematotoxic perspective

CD47, a transmembrane protein, acts as a do not eat me signal that is overexpressed in many tumor cell types, thereby forming a signaling axis with its ligand signal regulatory protein alpha (SIRP alpha) and enabling the tumor cells to escape from macrophage-mediated phagocytosis. Several clinical trials with CD47 targeting agents are underway and have achieved impressive results preliminarily. However, hematotoxicity (particularly anemia) has emerged as the most common side effect that cannot be neglected. In the development of CD47 targeting agents, various methods have been used to mitigate this toxicity. In this review, we summarized five strategies used to alleviate CD47 blockade-induced hematotoxicity, as follows: change in the mode of administration; dual targeting bispecific antibodies of CD47; CD47 antibodies/SIRP alpha fusion proteins with negligible red blood cell binding; anti-SIRP alpha antibodies; and glutaminyl-peptide cyclotransferase like inhibitors. With these strategies, the development of CD47 targeting agents can be improved.

Automated summary

The development of CD47 targeting agents faces hematotoxicity as a common side effect, but strategies such as changing the mode of administration and using bispecific antibodies can mitigate this issue.